NEO  valuation analysis

Basics
Name: NeoGenomics, Inc
Description: NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, as well as laboratories in Switzerland and Singapore. (more)
Industry: Diagnostics & Research
Last 10Q10Qs are quarterly reports which contain a company's financial figures. We use these to calculate the FFER.: Oct 27, 2020
Market cap: $5.38B (612th)
Sales(TTM): $425.32M (1139th)
Earnings(TTM): -$4.95M (974th)

Value
FFER: 3.35*
Actual price: $48.43
* Earnings were reported Feb 25, 2021 but we do not have the financials for this quarter. This is likely because the company has not yet released them. However, it might also be a problem with data quality. Regardless, you should take the FFER above with a grain of salt until we get updated financials.

Prices as of EOD 2021-03-03
Price & Estimates
Sales & Earnings history (TTM)
Notable
  • NeoGenomics, Inc's earnings decreased from $2.06M to -$4.95M in the last year.
  • NeoGenomics, Inc's operating income decreased from $13.51M to -$17.21M in the last year.
Earnings / MarketCap
NeoGenomics, Inc
"Diagnostics & Research" industry
Sales / MarketCap
NeoGenomics, Inc
"Diagnostics & Research" industry
Book / MarketCap
NeoGenomics, Inc
"Diagnostics & Research" industry
Equity / Assets
NeoGenomics, Inc
"Diagnostics & Research" industry